Article Text

Download PDFPDF

Pulmonary puzzle
Free

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

ANSWER

From the question on page 746

The differential diagnosis for pulmonary infiltrates in the immunocompromised host includes opportunistic infections, drug toxicity, alveolar haemorrhage and progression of the primary disease. The diagnostic yield of bronchoscopy in immunocompromised patients with lung infiltrates is variable with a higher yield (∼81%) for infectious aetiologies. On the basis of the larvae in the bronchoalveolar lavage fluid, our case was diagnosed as Strongyloides hyperinfection.

Strongyloidiasis is caused by an infection with Strongyloides stercoralis, a helminth that can complete its life cycle entirely within the human host.1 This autoinfection permits the organism to persist for decades and allows hyperinfection to occur in states of impaired cell-mediated immunity.2 Detection of a large number of larvae in the stool and/or bronchoalveolar lavage fluid or sputum is a hallmark of hyperinfection. The diagnosis requires a high index of suspicion and patients who have peripheral eosinophilia, serpiginous rash or history of soil exposure in tropical and subtropical areas should be screened by stool studies before any form of immunosuppression. In disseminated disease or steroid exposure eosinophilia may be absent.

The respiratory symptoms in strongyloidosis are caused by the migrating larvae producing alveolar haemorrhage, oedema or inflammatory changes. Adult worms are known to cause chronic bronchitis or asthma-like symptoms. The chest radiograph or a CT scan in those with clinical signs and symptoms will usually show abnormal findings including fine miliary nodules or diffuse reticular infiltrates. As the infection progresses there may be bronchopneumonia with scattered ill-defined alveolar, segmental or even lobar opacities similar to those seen in Löffler’s syndrome or eosinophilic pneumonitis.

The current treatment of choice for strongyloidiasis is ivermectin with albendazole as an alternative. Our patient was treated with ivermectin for 5 days. He was extubated and his nodular infiltrates cleared slowly over 6 weeks.

REFERENCES

View Abstract

Linked Articles